III. Mechanism
IV. Dose: Menomune
- Adult: 0.5 ml SC every 3 years
- Intramuscular may be preferred over subcutaneous route
- Intramuscular Injection reduces adverse effects
- Local erythema (11% for IM, 32% for SC)
- Headache (3% for IM and 12% for SC)
- Intramuscular has same efficacy as subcutaneous route
- Intramuscular Injection reduces adverse effects
V. Efficacy
- Like Menactra, Menomune has a high seroconversion rate (98%-100%)
- However Menomune duration is much shorter
- Menomune duration lasts 3 years in school age children and less in infants
VI. Precautions: Safety
- No longer contains Thimerosal
- Approved for all ages
- Safe in Human Immunodeficiency Virus (HIV)
VII. Adverse effects
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Pharmacologic Substance (T121) , Immunologic Factor (T129) |
MSH | D022401 |
French | Menomune |
English | menomune, Sanofi Pasteur Brand of Meningococcal Polysaccharide Vaccine, Menomune |